Recognition and accommodation at the androgen receptor coactivator binding interface

被引:179
作者
Hur, E
Pfaff, SJ
Payne, ES
Gron, H
Buehrer, BM
Fletterick, RJ [1 ]
机构
[1] Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA USA
[2] Karo Bio, Durham, NC USA
[3] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA USA
来源
PLOS BIOLOGY | 2004年 / 2卷 / 09期
关键词
D O I
10.1371/journal.pbio.0020274
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostate cancer is a leading killer of men in the industrialized world. Underlying this disease is the aberrant action of the androgen receptor (AR). AR is distinguished from other nuclear receptors in that after hormone binding, it preferentially responds to a specialized set of coactivators bearing aromatic-rich motifs, while responding poorly to coactivators bearing the leucine-rich "NR box" motifs favored by other nuclear receptors. Under normal conditions, interactions with these AR-specific coactivators through aromatic-rich motifs underlie targeted gene transcription. However, during prostate cancer, abnormal association with such coactivators, as well as with coactivators containing canonical leucine-rich motifs, promotes disease progression. To understand the paradox of this unusual selectivity, we have derived a complete set of peptide motifs that interact with AR using phage display. Binding affinities were measured for a selected set of these peptides and their interactions with AR determined by X-ray crystallography. Structures of AR in complex with FxxLF, LxxLL, FxxLW, WxxLF, WxxVW, FxxFF, and FxxYF motifs reveal a changing surface of the AR coactivator binding interface that permits accommodation of both AR-specific aromatic-rich motifs and canonical leucine-rich motifs. Induced fit provides perfect mating of the motifs representing the known family of AR coactivators and suggests a framework for the design of AR coactivator antagonists.
引用
收藏
页码:1303 / 1312
页数:10
相关论文
共 38 条
[1]  
Alen P, 1999, MOL CELL BIOL, V19, P6085
[2]   A gene-expression inhibitor that targets an α-helix-mediated protein interaction [J].
Asada, S ;
Choi, YM ;
Uesugi, M .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2003, 125 (17) :4992-4993
[3]   Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition [J].
Bledsoe, RK ;
Montana, VG ;
Stanley, TB ;
Delves, CJ ;
Apolito, CJ ;
McKee, DD ;
Consler, TG ;
Parks, DJ ;
Stewart, EL ;
Willson, TM ;
Lambert, MH ;
Moore, JT ;
Pearce, KH ;
Xu, HE .
CELL, 2002, 110 (01) :93-105
[4]  
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[5]  
Chang CY, 1999, MOL CELL BIOL, V19, P8226
[6]   Androgen receptors in prostate cancer [J].
Culig, Z ;
Klocker, H ;
Bartsch, G ;
Hobisch, A .
ENDOCRINE-RELATED CANCER, 2002, 9 (03) :155-170
[7]   Structure and specificity of nuclear receptor-coactivator interactions [J].
Darimont, BD ;
Wagner, RL ;
Apriletti, JW ;
Stallcup, MR ;
Kushner, PJ ;
Baxter, JD ;
Fletterick, RJ ;
Yamamoto, KR .
GENES & DEVELOPMENT, 1998, 12 (21) :3343-3356
[8]  
DeLano W., PYMOL MOL GRAPHICS S
[9]   Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): Multiple motifs with different binding specificities [J].
Ding, XF ;
Anderson, CM ;
Ma, H ;
Hong, H ;
Uht, RM ;
Kushner, PJ ;
Stallcup, MR .
MOLECULAR ENDOCRINOLOGY, 1998, 12 (02) :302-313
[10]   Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2 [J].
Geistlinger, TR ;
Guy, RK .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2003, 125 (23) :6852-6853